Keywords
Last Name
Institution

Serge Jabbour

TitleProfessor
InstitutionThomas Jefferson University
DepartmentEndocrinology & Metabolism
Address800 Walnut Street
Philadelphia PA 19107
Phone215-955-1925
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, Guja C. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes Obes Metab. 2018 Mar 23. PMID: 29573139.
      View in: PubMed
    2. Cunningham AT, Delgado DJ, Jackson JD, Crawford AG, Jabbour S, Lieberthal RD, Diaz V, LaNoue M. Evaluation of an Ongoing Diabetes Group Medical Visit in a Family Medicine Practice. J Am Board Fam Med. 2018 Mar-Apr; 31(2):279-281. PMID: 29535245.
      View in: PubMed
    3. Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab. 2018 Feb 23. PMID: 29473704.
      View in: PubMed
    4. Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. 2018 Jan 05. PMID: 29316164.
      View in: PubMed
    5. Caspard H, Jabbour S, Hammar N, Fenici P, Sheehan JJ, Kosiborod M. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. Diabetes Obes Metab. 2018 Mar; 20(3):667-671. PMID: 29077244.
      View in: PubMed
    6. Shohat N, Tarabichi M, Tischler EH, Jabbour S, Parvizi J. Serum Fructosamine: A Simple and Inexpensive Test for Assessing Preoperative Glycemic Control. J Bone Joint Surg Am. 2017 Nov 15; 99(22):1900-1907. PMID: 29135663.
      View in: PubMed
    7. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018 Mar; 20(3):620-628. PMID: 28950419.
      View in: PubMed
    8. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 10 17; 318(15):1460-1470. PMID: 29049653.
      View in: PubMed
    9. Warren ML, Chaykin LB, Jabbour S, Sheikh-Ali M, Hansen CT, Nielsen TSS, Norwood P. Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clin Diabetes. 2017 Apr; 35(2):90-95. PMID: 28442823.
      View in: PubMed
    10. Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017 Jun; 19(6):858-865. PMID: 28124817.
      View in: PubMed
    11. Pappu R, Jabbour SA, Reginato AM, Reginato AJ. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2017 Mar; 36(3):735. PMID: 28091807.
      View in: PubMed
    12. Pappu R, Jabbour SA, Regianto AM, Reginato AJ. Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2016 Dec; 35(12):3081-3087. PMID: 27815654.
      View in: PubMed
    13. Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Dec; 4(12):1004-1016. PMID: 27651331.
      View in: PubMed
    14. Jabbour S. Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes? Expert Opin Pharmacother. 2014 Dec; 15(18):2751-3. PMID: 25346092.
      View in: PubMed
    15. Burkhart RA, Gerber SM, Tholey RM, Lamb KM, Somasundaram A, McIntyre CA, Fradkin EC, Ashok AP, Felte RF, Mehta JM, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, Winter JM. Incidence and severity of pancreatogenic diabetes after pancreatic resection. J Gastrointest Surg. 2015 Feb; 19(2):217-25. PMID: 25316483.
      View in: PubMed
    16. Mehta JM, Miller JL, Cannon AJ, Mardekian SK, Kenyon LC, Jabbour SA. Ovarian leydig cell hyperplasia: an unusual case of virilization in a postmenopausal woman. Case Rep Endocrinol. 2014; 2014:762745. PMID: 25045549.
      View in: PubMed
    17. Jabbour SA, Jabbour SA. SGLT2 inhibitors to control Glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med. 2014 Jan; 126(1):111-7. PMID: 24393758.
      View in: PubMed
    18. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2014 Mar; 37(3):740-50. PMID: 24144654.
      View in: PubMed
    19. Jabbour S, Miller JL. Collaboration designed to increase translation of diabetes research outcomes into clinical practice. Clin Ther. 2013 May; 35(5):712-3. PMID: 23688535.
      View in: PubMed
    20. Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012 Jul; 124(4):62-73. PMID: 22913895.
      View in: PubMed
    21. Intenzo C, Jabbour S, Miller JL, Ahmed I, Furlong K, Kushen M, Kim SM, Capuzzi DM. Subclinical hyperthyroidism: current concepts and scintigraphic imaging. Clin Nucl Med. 2011 Sep; 36(9):e107-13. PMID: 21825836.
      View in: PubMed
    22. Bischoff LA, Jabbour SA, Miller JL. Exenatide once weekly in type 2 diabetes mellitus. Expert Opin Pharmacother. 2011 Jun; 12(8):1297-1303. PMID: 21548720.
      View in: PubMed
    23. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes. 2011 Apr; 18(2):148-52. PMID: 21522002.
      View in: PubMed
    24. Velasco G, Savarese V, Sandorfi N, Jimenez SA, Jabbour S. 46, XX SRY-positive male syndrome presenting with primary hypogonadism in the setting of scleroderma. Endocr Pract. 2011 Jan-Feb; 17(1):95-8. PMID: 20841307.
      View in: PubMed
    25. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011 Jan; 123(1):15-23. PMID: 21293080.
      View in: PubMed
    26. Jabbour SA. Skin manifestations of hormone-secreting tumors. Dermatol Ther. 2010 Nov-Dec; 23(6):643-50. PMID: 21054708.
      View in: PubMed
    27. Ahmed I, Jabbour SA. Visual vignette. Endocr Pract. 2009 Nov-Dec; 15(7):766. PMID: 19625238.
      View in: PubMed
    28. Critchell CD, Savarese V, Callahan A, Aboud C, Jabbour S, Marik P. Accuracy of bedside capillary blood glucose measurements in critically ill patients. Intensive Care Med. 2007 Dec; 33(12):2079-84. PMID: 17763842.
      View in: PubMed
    29. Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM, Mitchell EP. Scintigraphic imaging of body neuroendocrine tumors. Radiographics. 2007 Sep-Oct; 27(5):1355-69. PMID: 17848696.
      View in: PubMed
    30. Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb JE. Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. J Hosp Med. 2007 Jul; 2(4):234-40. PMID: 17702035.
      View in: PubMed
    31. Rubin DJ, Moshang J, Jabbour SA. Diabetes knowledge: are resident physicians and nurses adequately prepared to manage diabetes? Endocr Pract. 2007 Jan-Feb; 13(1):17-21. PMID: 17360296.
      View in: PubMed
    32. Jabbour SA. Endocrinology in dermatology. Clin Dermatol. 2006 Jul-Aug; 24(4):235-6. PMID: 16828403.
      View in: PubMed
    33. Jabbour SA, Davidovici BB, Wolf R. Rare syndromes. Clin Dermatol. 2006 Jul-Aug; 24(4):299-316. PMID: 16828412.
      View in: PubMed
    34. Rosenberg DE, Jabbour SA, Goldstein BJ. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab. 2005 Nov; 7(6):642-53. PMID: 16219008.
      View in: PubMed
    35. Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med. 2005 Oct; 35(4):257-65. PMID: 16150246.
      View in: PubMed
    36. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004 Apr; 20(4):565-72. PMID: 15119994.
      View in: PubMed
    37. Intenzo CM, dePapp AE, Jabbour S, Miller JL, Kim SM, Capuzzi DM. Scintigraphic manifestations of thyrotoxicosis. Radiographics. 2003 Jul-Aug; 23(4):857-69. PMID: 12853661.
      View in: PubMed
    38. Wu X, Hardy VE, Joseph JI, Jabbour S, Mahadev K, Zhu L, Goldstein BJ. Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition. Metabolism. 2003 Jun; 52(6):705-12. PMID: 12800095.
      View in: PubMed
    39. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003; 4(5):315-31. PMID: 12688837.
      View in: PubMed
    40. Dagher HN, Aboujaoude ZC, Jabbour SA. Chronic urticaria: an unusual initial manifestation of primary hyperparathyroidism. Endocr Pract. 2002 Jan-Feb; 8(1):47-9. PMID: 11939760.
      View in: PubMed
    Jabbour's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _